The Synthesis and Properties of Mitochondrial Targeted Iron Chelators

Overview

Journal Biometals

Specialty Biochemistry

Date 2022 Apr 2

PMID 35366134

Authors

Agostino Cilibrizzi

Charareh Pourzand

Vincenzo Abbate

Olivier Reelfs

Laura Versari

Giuseppe Floresta

Robert Hider

Affiliations

Soon will be listed here.

Abstract

Iron levels in mitochondria are critically important for the normal functioning of the organelle. Abnormal levels of iron and the associated formation of toxic oxygen radicals have been linked to a wide range of diseases and consequently it is important to be able to both monitor and control levels of the mitochondrial labile iron pool. To this end a series of iron chelators which are targeted to mitochondria have been designed. This overview describes the synthesis of some of these molecules and their application in monitoring mitochondrial labile iron pools and in selectively removing excess iron from mitochondria.

Citing Articles

The role of mitochondria in iron overload-induced damage.

Zhao Y, Yang M, Liang X J Transl Med. 2024; 22(1):1057.

PMID: 39587666 PMC: 11587765. DOI: 10.1186/s12967-024-05740-4.

Emerging antioxidant therapies in Friedreich's ataxia.

Edzeamey F, Ramchunder Z, Pourzand C, Anjomani Virmouni S Front Pharmacol. 2024; 15:1359618.

PMID: 38379897 PMC: 10876797. DOI: 10.3389/fphar.2024.1359618.

MitoNEET Provides Cardioprotection via Reducing Oxidative Damage and Conserving Mitochondrial Function.

Tam E, Sweeney G Int J Mol Sci. 2024; 25(1).

PMID: 38203651 PMC: 10779211. DOI: 10.3390/ijms25010480.

Optical Imaging Opportunities to Inspect the Nature of Cytosolic Iron Pools.

Hider R, Pourzand C, Ma Y, Cilibrizzi A Molecules. 2023; 28(18).

PMID: 37764245 PMC: 10537325. DOI: 10.3390/molecules28186467.

Total Bio-Based Material for Drug Delivery and Iron Chelation to Fight Cancer through Antimicrobial Activity.

Patamia V, Zagni C, Fiorenza R, Fuochi V, Dattilo S, Riccobene P Nanomaterials (Basel). 2023; 13(14).

PMID: 37513047 PMC: 10384306. DOI: 10.3390/nano13142036.

References

Abbate V, Reelfs O, Hider R, Pourzand C . Design of novel fluorescent mitochondria-targeted peptides with iron-selective sensing activity. Biochem J. 2015; 469(3):357-66. DOI: 10.1042/BJ20150149. View

Alta R, Vitorino H, Goswami D, Machini M, Esposito B . Triphenylphosphonium-desferrioxamine as a candidate mitochondrial iron chelator. Biometals. 2017; 30(5):709-718. DOI: 10.1007/s10534-017-0039-5. View

Alta R, Vitorino H, Goswami D, Liria C, Wisnovsky S, Kelley S . Mitochondria-penetrating peptides conjugated to desferrioxamine as chelators for mitochondrial labile iron. PLoS One. 2017; 12(2):e0171729. PMC: 5298241. DOI: 10.1371/journal.pone.0171729. View

Aroun A, Zhong J, Tyrrell R, Pourzand C . Iron, oxidative stress and the example of solar ultraviolet A radiation. Photochem Photobiol Sci. 2011; 11(1):118-34. DOI: 10.1039/c1pp05204g. View

Chiang S, Huang M, Park K, Richardson D . Antioxidant defense mechanisms and its dysfunctional regulation in the mitochondrial disease, Friedreich's ataxia. Free Radic Biol Med. 2020; 159:177-188. DOI: 10.1016/j.freeradbiomed.2020.07.019. View

Cilibrizzi A, Abbate V, Chen Y, Ma Y, Zhou T, Hider R . Hydroxypyridinone Journey into Metal Chelation. Chem Rev. 2018; 118(16):7657-7701. DOI: 10.1021/acs.chemrev.8b00254. View

Cloonan S, Glass K, Laucho-Contreras M, Bhashyam A, Cervo M, Pabon M . Mitochondrial iron chelation ameliorates cigarette smoke-induced bronchitis and emphysema in mice. Nat Med. 2016; 22(2):163-74. PMC: 4742374. DOI: 10.1038/nm.4021. View

Connor J, Snyder B, Beard J, Fine R, Mufson E . Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res. 1992; 31(2):327-35. DOI: 10.1002/jnr.490310214. View

Deus C, Pereira S, Cunha-Oliveira T, Teixeira J, Simoes R, Cagide F . A mitochondria-targeted caffeic acid derivative reverts cellular and mitochondrial defects in human skin fibroblasts from male sporadic Parkinson's disease patients. Redox Biol. 2021; 45:102037. PMC: 8220403. DOI: 10.1016/j.redox.2021.102037. View

10.

Devos D, Moreau C, Devedjian J, Kluza J, Petrault M, Laloux C . Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal. 2013; 21(2):195-210. PMC: 4060813. DOI: 10.1089/ars.2013.5593. View

11.

Dexter D, WELLS F, Agid F, Agid Y, Lees A, Jenner P . Increased nigral iron content in postmortem parkinsonian brain. Lancet. 1987; 2(8569):1219-20. DOI: 10.1016/s0140-6736(87)91361-4. View

12.

Dissemond J, Schneider L, Brenneisen P, Briviba K, Wenk J, Wlaschek M . Protective and determining factors for the overall lipid peroxidation in ultraviolet A1-irradiated fibroblasts: in vitro and in vivo investigations. Br J Dermatol. 2003; 149(2):341-9. DOI: 10.1046/j.1365-2133.2003.05457.x. View

13.

Futaki S . Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. Biopolymers. 2005; 84(3):241-9. DOI: 10.1002/bip.20421. View

14.

Gao J, Zhou Q, Wu D, Chen L . Mitochondrial iron metabolism and its role in diseases. Clin Chim Acta. 2020; 513:6-12. DOI: 10.1016/j.cca.2020.12.005. View

15.

Hider R, Kong X . Chemistry and biology of siderophores. Nat Prod Rep. 2010; 27(5):637-57. DOI: 10.1039/b906679a. View

16.

Hirayama T, Tsuboi H, Niwa M, Miki A, Kadota S, Ikeshita Y . A universal fluorogenic switch for Fe(ii) ion based on N-oxide chemistry permits the visualization of intracellular redox equilibrium shift towards labile iron in hypoxic tumor cells. Chem Sci. 2017; 8(7):4858-4866. PMC: 5603896. DOI: 10.1039/c6sc05457a. View

17.

Hirayama T, Miki A, Nagasawa H . Organelle-specific analysis of labile Fe(ii) during ferroptosis by using a cocktail of various colour organelle-targeted fluorescent probes. Metallomics. 2018; 11(1):111-117. DOI: 10.1039/c8mt00212f. View

18.

Horton K, Stewart K, Fonseca S, Guo Q, Kelley S . Mitochondria-penetrating peptides. Chem Biol. 2008; 15(4):375-82. DOI: 10.1016/j.chembiol.2008.03.015. View

19.

Ke Y, Qian Z . Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2003; 2(4):246-53. DOI: 10.1016/s1474-4422(03)00353-3. View

20.

Lim C, Kalinowski D, Richardson D . Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class. Mol Pharmacol. 2008; 74(1):225-35. DOI: 10.1124/mol.108.046847. View